Foyston, Gordon, & Payne Inc Novartis Ag Transaction History

Foyston, Gordon, & Payne Inc

$392 Million
Q3 2024

A detailed history of Foyston, Gordon, & Payne Inc transactions in Novartis Ag stock. As of the latest transaction made, Foyston, Gordon, & Payne Inc holds 10,851 shares of NVS stock, worth $1.07 Million. This represents 0.32% of its overall portfolio holdings.

Number of Shares

10,851

Previous 23,856 54.51%

Holding current value

$1.07 Million

Previous $2.54 Million 50.85%

% of portfolio

0.32%

Previous 0.64%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$106.13 - $120.89 $1.38 Million - $1.57 Million	-13,005 Reduced 54.51%	10,851 $1.25 Million
Q2 2024 Jul 30, 2024	SELL	$92.57 - $107.37 $97,568 - $113,167	-1,054 Reduced 4.23%	23,856 $2.54 Million
Q1 2024 May 07, 2024	SELL	$95.27 - $108.47 $52,017 - $59,224	-546 Reduced 2.14%	24,910 $2.41 Million
Q4 2023 Feb 07, 2024	BUY	$92.27 - $101.54 $1.4 Million - $1.54 Million	15,166 Added 147.39%	25,456 $2.57 Million
Q3 2023 Oct 26, 2023	SELL	$94.73 - $105.13 $9.73 Million - $10.8 Million	-102,752 Reduced 90.9%	10,290 $1.05 Million
Q2 2023 Aug 01, 2023	BUY	$92.52 - $104.91 $7.75 Million - $8.78 Million	83,712 Added 285.41%	113,042 $11.4 Million
Q1 2023 May 03, 2023	SELL	$80.03 - $92.81 $53,860 - $62,461	-673 Reduced 2.24%	29,330 $2.7 Million
Q4 2022 Feb 09, 2023	SELL	$75.55 - $92.52 $54,018 - $66,151	-715 Reduced 2.33%	30,003 $2.72 Million
Q3 2022 Nov 04, 2022	BUY	$74.61 - $87.26 $1.46 Million - $1.71 Million	19,546 Added 174.96%	30,718 $2.34 Million
Q2 2022 Aug 11, 2022	SELL	$80.52 - $93.75 $1.65 Million - $1.92 Million	-20,508 Reduced 64.73%	11,172 $2.69 Million
Q1 2022 Apr 27, 2022	BUY	$80.11 - $90.62 $2,803 - $3,171	35 Added 0.11%	31,680 $2.78 Million
Q4 2021 Feb 11, 2022	SELL	$79.7 - $88.13 $928,026 - $1.03 Million	-11,644 Reduced 26.9%	31,645 $2.77 Million
Q3 2021 Nov 12, 2021	SELL	$81.78 - $95.14 $18,809 - $21,882	-230 Reduced 0.53%	43,289 $3.54 Million
Q2 2021 Aug 06, 2021	SELL	$85.24 - $94.15 $1.1 Million - $1.21 Million	-12,854 Reduced 22.8%	43,519 $3.97 Million
Q1 2021 May 14, 2021	SELL	$83.5 - $98.47 $73,229 - $86,358	-877 Reduced 1.53%	56,373 $4.82 Million
Q4 2020 Feb 12, 2021	SELL	$78.07 - $94.43 $237,254 - $286,972	-3,039 Reduced 5.04%	57,250 $5.41 Million
Q3 2020 Nov 12, 2020	BUY	$82.14 - $91.0 $126,002 - $139,594	1,534 Added 2.61%	60,289 $5.24 Million
Q2 2020 Aug 14, 2020	SELL	$80.93 - $91.1 $962,014 - $1.08 Million	-11,887 Reduced 16.83%	58,755 $5.13 Million
Q1 2020 May 15, 2020	SELL	$70.67 - $99.01 $125,156 - $175,346	-1,771 Reduced 2.45%	70,642 $5.82 Million
Q4 2019 Feb 14, 2020	BUY	$84.35 - $95.37 $166,928 - $188,737	1,979 Added 2.81%	72,413 $6.86 Million
Q3 2019 Nov 14, 2019	SELL	$85.54 - $94.26 $866,776 - $955,136	-10,133 Reduced 12.58%	70,434 $6.12 Million
Q2 2019 Aug 15, 2019	BUY	$75.4 - $92.8 $1,734 - $2,134	23 Added 0.03%	80,567 $7.36 Million
Q1 2019 May 14, 2019	SELL	$75.32 - $86.15 $2,334 - $2,670	-31 Reduced 0.04%	80,544 $7.74 Million
Q4 2018 Feb 08, 2019	SELL	$73.66 - $82.02 $519,008 - $577,912	-7,046 Reduced 8.04%	80,575 $6.91 Million
Q3 2018 Nov 02, 2018	BUY	$66.94 - $77.43 $43,176 - $49,942	645 Added 0.74%	87,621 $7.55 Million
Q2 2018 Aug 10, 2018	BUY	$64.91 - $73.36 $183,046 - $206,875	2,820 Added 3.35%	86,976 $6.57 Million
Q1 2018 May 14, 2018	SELL	$70.39 - $84.15 $47,090 - $56,296	-669 Reduced 0.79%	84,156 $6.8 Million
Q4 2017 Feb 14, 2018	SELL	$72.33 - $77.64 $6 Million - $6.44 Million	-82,898 Reduced 49.43%	84,825 $7.12 Million
Q3 2017 Nov 14, 2017	BUY	$74.14 - $77.27 $5.98 Million - $6.24 Million	80,693 Added 92.72%	167,723 $14.4 Million
Q2 2017 Aug 14, 2017	BUY	N/A	87,030	87,030 $7.26 Million

Others Institutions Holding NVS

# of Institutions

1,437

Shares Held

131M

Call Options Held

1.12M

Put Options Held

1.83M

View Full List

About NOVARTIS AG

Ticker NVS
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,151,000,064
Market Cap $212B
Description
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatol...

More about NVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Foyston, Gordon, & Payne Inc, based on Form 13F filings with the SEC.

News

Stay updated on Foyston, Gordon, & Payne Inc with notifications on news.

Account

Foyston, Gordon, & Payne Inc Novartis Ag Transaction History